Sanz-Álvarez, M.; Martín-Aparicio, E.; Luque, M.; Zazo, S.; Martínez-Useros, J.; Eroles, P.; Rovira, A.; Albanell, J.; Madoz-Gúrpide, J.; Rojo, F.
The Novel Oral mTORC1/2 Inhibitor TAK-228 Reverses Trastuzumab Resistance in HER2-Positive Breast Cancer Models. Cancers 2021, 13, 2778.
https://doi.org/10.3390/cancers13112778
AMA Style
Sanz-Álvarez M, Martín-Aparicio E, Luque M, Zazo S, Martínez-Useros J, Eroles P, Rovira A, Albanell J, Madoz-Gúrpide J, Rojo F.
The Novel Oral mTORC1/2 Inhibitor TAK-228 Reverses Trastuzumab Resistance in HER2-Positive Breast Cancer Models. Cancers. 2021; 13(11):2778.
https://doi.org/10.3390/cancers13112778
Chicago/Turabian Style
Sanz-Álvarez, Marta, Ester Martín-Aparicio, Melani Luque, Sandra Zazo, Javier Martínez-Useros, Pilar Eroles, Ana Rovira, Joan Albanell, Juan Madoz-Gúrpide, and Federico Rojo.
2021. "The Novel Oral mTORC1/2 Inhibitor TAK-228 Reverses Trastuzumab Resistance in HER2-Positive Breast Cancer Models" Cancers 13, no. 11: 2778.
https://doi.org/10.3390/cancers13112778
APA Style
Sanz-Álvarez, M., Martín-Aparicio, E., Luque, M., Zazo, S., Martínez-Useros, J., Eroles, P., Rovira, A., Albanell, J., Madoz-Gúrpide, J., & Rojo, F.
(2021). The Novel Oral mTORC1/2 Inhibitor TAK-228 Reverses Trastuzumab Resistance in HER2-Positive Breast Cancer Models. Cancers, 13(11), 2778.
https://doi.org/10.3390/cancers13112778